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Introduction

Migraine is a common, multifactorial,
disabling primary headache disorder.1,2
According
to
the
International
Classification of Headache Disorders, 3rd
edition (beta version), chronic migraine
refers to a headache occurring on 15 or
more days per month for more than 3
months which has the features of migraine
on at least 8 days per month.2 According to
the National Health Interview Survey in
2012, the overall prevalence of migraine or
severe headache is 14.2% in the United
States, with 19.1% of females and 9.0% of
males affected with substantial variations
depending on age.3 Migraine ranked as the
third most common cause of disability
worldwide in individuals under 50 as
reported by the Global Burden of Disease
[page 18]
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Chronic migraine is a frequent and
debilitating condition affecting 14% of the
general population. This prospective observational pilot study investigated whether
men with chronic migraine have lower than
expected total serum testosterone levels. We
identified 14 men ages 26-51 at our
Institution who fulfilled the ICHD-3b criteria for chronic migraine and obtained serum
total testosterone levels. The mean total
testosterone level in our 14 patients was 322
ng/dL (range: 120-542 ng/dL) which is in
the lower 5% of the reference range for our
laboratory (300-1080 ng/dL). Men with
chronic migraine had lower total testosterone levels compared to published agematched normative median values by a
median difference of 62 ng/dL (P=0.0494).
This finding suggests that hypothalamic
regulation is altered in patients with chronic
migraine. Further studies are warranted to
determine whether testosterone supplementation in men with chronic migraine reduces
the number of headaches or the associated
symptoms of hypogonadism.
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Survey 2015.4 Migraines are considered to
involve the hypothalamus, brainstem, and
cortex which regulates autonomic, affective, cognitive, and sensory functions.1
Chronic migraine may affect hypothalamic
hormonal secretion. Many men with chronic migraine exhibit symptoms that are frequently
seen
with
hypogonadism
(depressed mood, reduced energy, difficulty
concentrating).
Positron emission tomography (PET)
has shown hypothalamic activation in spontaneous migraine attacks which persists
after headache relief by sumatriptan.5,6
Attention has focused on the function of the
hypothalamus in circadian rhythms, pain
control coordinating the activity of the sympathetic and parasympathetic nervous systems, and in maintaining homeostasis.1,5,7
In addition, the hypothalamus is integrally
involved with the body’s responses to
stress.7 The hypothalamus secretes
gonadotropin-releasing hormone (GnRH)
which stimulates the anterior pituitary gland
to release luteinizing hormone (LH) from
the gonadotrophs.8 The receptors for LH are
located on Leydig cells in the testis which
synthesize testosterone following LH stimulation.8 Figure 1 depicts the hypothalamic
regulation of testosterone.
There are no reports known to the
authors on the effect that chronic migraine
may have on testosterone levels in men. We
investigated whether men with chronic
migraine have lower than expected total
serum testosterone levels. In this prospective pilot study, we present our findings pertaining to the interaction between chronic
migraine and testosterone levels. We also
discuss the impact of chronic migraine on
the regulation of the hypothalamo-pituitarygonadal axis.
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Testosterone levels in men
with chronic migraine

Materials and Methods
Patient population

Under an institutional review board
(IRB) approved protocol, we prospectively
identified 14 men who fulfilled the ICHD3b criteria for chronic migraine without opioid or barbiturate overuse at our Institution.
These patients were evaluated by a neurologist at our Institution’s outpatient clinic in a
metropolitan community. All men obtained
serum total testosterone levels. These values were compared to the local laboratory
normal values and to published agematched controls.9

Statistical analysis

Data are presented in listings and summarized as either mean (SD) or median
[Neurology International 2019; 11:8079]
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(interquartile range: 25th %-tile & 75th %tile). To test whether the testosterone distribution amongst those men with migraines
differed from a control population distribution, the median testosterone from a published age-specific control population was
matched to the age-specific testosterone
level for the 14 migraine subjects.9 To
assess whether these age-matched groups
differed, Wilcoxon Signed Rank test was
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Figure 1. Hypothalamic regulation of
testosterone.
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In our pilot study, men with
chronic migraine had statistically significant lower total testosterone levels compared to an age-matched normative population, suggesting that hypothalamic regula-
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A total of 14 men fulfilled the criteria
for inclusion. The mean age was 36.1 years
(range: 26-51 years). The local laboratory
normal range for total testosterone was 3001080 ng/dL. Table 1 illustrates the total
testosterone levels of migraine patients
compared to published age-matched controls. The mean total testosterone level in
the 14 patients with chronic migraine was
322 ng/dL (range: 120-542 ng/dL).
For published age-matched controls, the
mean total testosterone level was 384 ng/dL
(SD=10.3). Six males (43%) had testosterone levels below the minimum of the
normal local laboratory range. Men with
chronic migraine had lower total testosterone levels compared to published agematched controls by a median difference of
62.0 ng/dL (interquartile range of 0.34 to
130). The Wilcoxon Signed rank statistic
revealed a statistically significant difference
between the two distributions (P=0.0494).

130). In addition, there was a statistically
significant difference between the two distributions (P=0.0494). Six males (43%) had
testosterone levels below the minimum of
the normal local laboratory range. Of note,
the mean total testosterone level in our 14
patients with chronic migraine was 322
ng/dL which is in the lower 5% of the reference range for our laboratory (300-1080
ng/dL). This finding supports that testosterone levels are very low in migraine
patients. Abnormality of the hypothalamuspituitary-gonadal axis is believed to be
involved in the pathogenesis of migraine.15
In Li and colleagues’ study of the levels of
HPG axis hormones serum FSH, LH, estradiol, progesterone, testosterone, prolactin,
and GnRH, they reported that these hormones were abnormal in migraineurs and
were associated with migraine-related clinical characteristics.15
Hypogonadism refers to “a clinical syndrome that results from failure of the testis
to produce physiological levels of testosterone (androgen deficiency) and a normal

us

Results

tion is altered in patients with chronic
migraine. We propose that the suppression
of the hypothalamic pituitary axis as a result
of chronic migraine inhibits the release of
GnRH resulting in secondary hypogonadism. A host of studies have investigated
the pathophysiology of the hypothalamus in
both cluster headache10 and chronic
migraine,1,5-7,11 however, a paucity of studies have explored the interaction between
testosterone levels and chronic migraine,
tension type headache (TTH), and cluster
headache.12,13 It has been suggested that
both male and female sex hormones could
influence the course of primary headaches,
specifically,
tension-type
headache,
migraine, and cluster headache.14 Romiti
and colleagues studied plasma testosterone
levels in cluster headache and non-cluster
headache controls.13 Plasma testosterone
levels were significantly lower during the
cluster attack and were within the reference
limits in the remission period of episodic
cluster headache.13 These authors suggest
that a decrease of plasma testosterone levels
in episodic cluster headache should be considered in relation to disordered rapid eye
movement (REM) sleep in cluster
headache.
The present study and that of Romiti et
al. highlighted testosterone levels in
migraine
and
cluster
headache,
respectively.13 Both studies reported that
testosterone levels were significantly lower
in the headache disorder group compared to
controls. We demonstrated that men with
chronic migraine had lower total testosterone levels compared to their agematched control by a median difference of
62 ng/dL (interquartile range of 0.34 to
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used to test for the testosterone distribution
difference. An a-priori two-sided significance level of 5% was used to interrogate
any observed difference.

Age
26
27
30
32
33
33
34
35
37
38
40
42
48
51

N

Table 1. Total testosterone levels of migraine patients compared to published age-matched controls.
Total testosterone of
migraine patients (ng/dL)

Normal for reference
lab (1=yes;0=no)

Total testosterone of published
age-matched controls (ng/dL)*

406
428
120
434
270
324
378
268
542
360
230
310
196
245

1
1
0
1
0
1
1
0
1
1
0
1
0
0

406
403
392
386
383
383
383
380
378
378
375
375
375
375

Normal Testosterone Range (Local Reference Lab): 300-1080 ng/dL. *See Kelsey et al. 2014.9
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the accompanying symptoms of hypogonadism.
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In this pilot study, men with chronic
migraine had statistically significant lower
total testosterone levels compared to an
age-matched normative population. Further
investigation is necessary to determine
whether testosterone supplementation in
men with chronic migraine reduces either
the number of headache days per month or
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number of spermatozoa due to disruption of
one or more levels of the hypothalamicpituitary-testicular axis”.16 Hypogonadal
symptoms include diminished libido,
fatigue, poor concentration, erectile dysfunction, and depressed mood in the setting
of low serum testosterone levels.17 Many
men with chronic migraine exhibit symptoms that are frequently seen with hypogonadism, specifically, depressed mood,
reduced energy, and difficulty concentrating. Testosterone supplementation has been
shown to be beneficial in improving both
hypogonadal symptoms and serum total
testosterone levels.16,17 Testosterone therapy in hypogonadal men has been shown to
be highly effective and safe for improving
lower urinary tract symtpoms, cardiometabolic risk, and major adverse cardiovascular
events18 as well as urinary and sexual function and quality of life.19 Testosterone
serves as a neuroprotective agent,20 suggesting a valuable role in the treatment of
chronic migraine. Continuous testosterone
has also been reported as beneficial in
reducing the severity of migraines in both
pre- and post-menopausal women.21 These
studies demonstrate that testosterone effectively treats migraine headaches in both
men and women and that low testosterone is
likely causal and not the result of migraines.
The strength of the present study is the
prospective evaluation of the possible role
of testosterone in migraine headaches as it
is far less studied than estrogen/progesterone. Our study is limited by its small
sample size. Prospective, randomized studies with a larger sample size are warranted
to permit generalizability of our results.

